Pressing for label change, vaccine giant Sanofi takes Seqirus influenza imbroglio to the FDA

Sanofi is challenging influenza rival Seqirus on the regulatory level, arguing labels for two of the CSL Limited subsidiary’s flu shots should be amended to reflect their mixed results in post-approval trials. Seqirus, for its part, says it stands behind the safety and efficacy of its vaccines.